Hormone replacement therapy [topp]
Plasma [bdsu]
cardiovascular risk factor [dsyn]
asymmetric dimethylarginine [aapp, phsu]
randomized [resa]
placebo controlled study [inpr, resa]
Health [idcn]
postmenopausal [tmco]
Women [popg]
prospective [resa]
randomized [resa]
placebo controlled study [inpr, resa]
investigated [ftcn]
Oral [spco]
Hormone replacement therapy [topp]
asymmetric dimethylarginine [aapp, phsu]
Endogenous [ftcn]
Inhibitor [qlco]
Nitric Oxide Synthase [aapp, enzy]
Independent [idcn]
coronary heart disease [dsyn]
effects [qlco]
Arginine [aapp, bacs, phsu]
symmetric dimethylarginine [aapp]
investigated [ftcn]
Health [idcn]
postmenopausal [tmco]
Women [popg]
Received [qlco]
Daily [tmco]
placebo [topp]
N NOS [aapp, imft]
Oral [spco]
Estradiol 2 MG [clnd]
N NOS [aapp, imft]
Combined [qlco]
Dydrogesterone 10 MG [clnd]
2-D [spco]
N NOS [aapp, imft]
trimegestone [orch, phsu]
mg% [qnco]
N NOS [aapp, imft]
asymmetric dimethylarginine [aapp, phsu]
Levels [qlco]
Reduced [qlco]
Active Treatment [topp]
Group [idcn]
Compared [acty]
baseline [bodm]
placebo [topp]
Largest [qnco]
reduction [npop]
asymmetric dimethylarginine [aapp, phsu]
Levels [qlco]
Observed [ftcn]
T-Group [edac]
T-Group [edac]
Arginine [aapp, bacs, phsu]
Levels [qlco]
Reduced [qlco]
Well [qlco]
symmetric dimethylarginine [aapp]
Levels [qlco]
2-D [spco]
Group [idcn]
Oral [spco]
Estradiol [horm, phsu, strd]
Estradiol [horm, phsu, strd]
Combined [qlco]
Dydrogesterone [horm, phsu, strd]
trimegestone [orch, phsu]
Reduced [qlco]
Plasma [bdsu]
Nitric Oxide Synthase Inhibitor [phsu]
asymmetric dimethylarginine [aapp, phsu]
reduction [npop]
Nitric Oxide Synthase [aapp, enzy]
Substrate [mnob]
Arginine [aapp, bacs, phsu]
T-Group [edac]
asymmetric dimethylarginine [aapp, phsu]
reduction [npop]
reflect [menp]
Increased [qnco]
production [ocac]
investigated [ftcn]
